Radioimmunoconjugates in Renal Cell Carcinoma
The long-awaited clinical benefits of radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) are being realized in a slow but steadily progressive fashion . The visualization of tumor foci no longer requires extensive manipulative steps to discriminate uptake of radiolabeled antibody by the tumor from that of the blood pool or normal tissues, and in therapeutic regimens significant tumor responses are becoming more common. However, the past decade of animal studies and clinical efforts utilizing radionuclide conjugated monoclonal antibodies (MAb) has demonstrated the vast complexities of the task at hand, and even as enthusiasm is growing, significant hurdles remain to be cleared if RIS and RIT are to achieve their anticipated clinical potential. We have been actively exploring the use of RIS and RIT in renal cell carcinoma (RCC) xenografts for 5 years and in clinical trials for approximately 2 years. This report will briefly review the progress to date and then in more detail will provide an overview of the key RIS and RIT issues that are being addressed by the scientific community.
KeywordsPermeability Toxicity HPLC Depression Iodine
Unable to display preview. Download preview PDF.
- 1.Larson SM (1990) Clinical radioimmunodetaction, overview and suggestions for standardization of clinical trials. Cancer Res 50 (Suppl): 892–898Google Scholar
- 2.Dayman RV, Figenshau RS, Bear A, Limas C (1985) Transplantation of human renal cell carcinoma into athymic mice. Cancer Res 45: 2650–2653Google Scholar
- 3.Williams RD, Elliot AY, Stein N, etal. (1978) In vitro cultivation of human renal cell cancer. In Vitro 14: 779–786Google Scholar
- 7.Vessella RL, Lange PH, Palme DF, Chiou RK, Elson MK, Wessels BW (1988) Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice. In: Rodwell JD (ed) Antibody-mediated delivery systems. Dekker, New York, pp 245–282Google Scholar
- 11.Langmuir VK, Sutherland RM (1988) Radiobiology of radioimmunotherapy: Current status. Antibody Immunocon Radiophar 1 (3): 195–211Google Scholar
- 13.Berkopec JM, Bradley BW, Wessels DF, Palme DF, Montilla L, Vessella RL (1989) Combined external beam irradiation (XRT) and radioimmunotherapy (RTT) on renal cell carcinoma xenografts. J Nucl Med 30 (5): 406Google Scholar
- 14.Vessella RL, Chiou RK, Grund FM, Elson MK, Johnson TK, Nowak JA, Palme DF, Lightner DJ, Mathisen ML, Wessels BW, Olson RE, Rittenhouse HG, Stroup SD, Lange PH (1987) Renal cell carcinoma (RCC) phase I–II trials with 131-I labeled monoclonal antibody A6H: Imaging and pharmacokinetic studies. Proc Am Assoc Cancer Res 28: 1525Google Scholar
- 15.Lightner DJ, Vessella RL, Chiour RK, Grand FM, Johnson TK, Elson MK, Wessels BW, Stroupe SD, Mathisen ML, Lange PH (1988) Renal cell carcinoma phase I–II trials with 1–131 monoclonal antibody (MoAb) A6H. Proc Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, vol 92, p 119Google Scholar
- 17.Griffin TW, Collins J, Bokhari F, Stochl M, Brill AB, Ito T, Emond G, Sands H (1990) Intraperitoneal immunoconjugates. Cancer Res 50 (Suppl): 103ls–1038sGoogle Scholar